Agreement of Susceptibility-Weighted Imaging (SWI) for Detecting Metastatic Brain Lesions Compared to Gadolinium-Enhanced THRIVE MRI Technique
Keywords:
Susceptibility-Weighted Imaging (SWI) , Metastatic brain lesion, Gadolinium-enhanced MRI brainAbstract
Introduction: To evaluate the sensitivity, agreement, and PPV of SWI for detecting metastatic brain lesions compared to Gadolinium-enhanced THRIVE MRI technique.
Methods: A retrospective review of the brain MRI of metastatic brain patients on SWI and Gadoliniumenhanced THRIVE MRI technique from January, 2016 to December, 2018 which interpreted by one radiologist with ten-year experience and one third-year resident-training radiologist. The sensitivity and PPV between the SWI and THRIVE techniques were calculated.
Results: A total of 17 patients with brain metastasis were enrolled. There were 11 patients (64.7%) with lung cancer, four (23.5%) with breast cancer, one (5.9%) with colon cancer, and one (5.9%) with lung and thyroid cancer. Among these 17 patients, the experienced radiologist detected 413 lesions, while the resident detected 401 lesions. According to the experienced radiologist's results, the sensitivity of the SWI for detecting metastatic brain lesions at different sites, compared to THRIVE, ranged from 0.20 - 0.36. The PPV at different sites ranged from 0.92 - 1.00. A high PPV was suggestive of a high chance of enhancement on THRIVE of microbleed area on SWI, which indicated metastatic brain lesions. Good to excellent inter-observer agreement regarding the ICC, and substantial agreement concerning the Kappa value, were noted. Therefore, both sequences for evaluating metastatic brain lesions can be confidently used by experienced radiologists and trainee-radiologist.
Conclusions: SWI has benefit for predicting hemorrhagic brain metastasis due to high PPV, especially when found coexisting with vasogenic brain edema or location at gray-white matter junction at cerebral hemisphere or cerebellar area.
Downloads
References
Gallego Perez Larraya J, Hildebrand J. Brain metastases. Handb Clin Neurol. 2014;121:1143-1157.
Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002;249(10):1357-1369.
Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park). 1999;13(7):941-961.
Tabouret E, Chinot O, Metellus P. Recent trends in epidemiology of brain metastases. Anticancer Res. 2012;32(11):4655-4662.
Alexandru D, Bota DA, Linskey ME. Epidemiology of central nervous system metastases. Prog Neurol Surg. 2012;25:13-29.
Barnholtz Sloan JS, Sloan AE, Davis FG. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Res Oncol. 2004;22(14):2865-2872.
Delattre JY, Krol G, Thaler HT. Distribution of brain metastases. Arch Neurol. 1988;45(7):741-744.
Lieu AS, Hwang SL, Howng SL, Chai CY. Brain tumors with hemorrhage. J Formos Med Assoc. 1999;98(5):365-367.
Yoo H, Jung E, Gwak HS. Surgical outcomes of hemorrhagic metastatic brain tumors. Cancer Res Treat. 2011;43(2):102.
Barajas RF Jr, Cha S. Metastasis in adult brain tumors. Neuroimaging Clin N Am. 2016;26(4):601-620.
Beckett KR, Moriarity AK, Langer JM. Safe use of contrast media: What the radiologist needs to know. Radiographics. 2015;35(6):1738-1750.
Liu C, Li W, Tong KA. Susceptibility-weighted imaging, and quantitative susceptibility mapping in the brain. J Magn Reson Imaging. 2015;42(1):23-41.
Franceschi AM, Moschos SJ, Anders CK, et al. Utility of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma. J Comput Assist Tomogr. 2016;40(5):803-805.
Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155-163.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
Fontana EJ, Benzinger T, Cobbs C. The evolving role of neurological imaging in neurooncology. J Neurooncol. 2014;119(3):491-502.
Walker MT, Kapoor V. Neuroimaging of parenchymal brain metastases. Cancer Treat Res. 2007;136:31-51
Zhang W, Ma XX, Ji YM. Haemorrhage detection in brain metastases of lung cancer patients using magnetic resonance imaging. J Int Med Res. 2009;37(4):1139-1144.
Fink KR, Fink JR. Imaging of brain metastases. Surg Neurol Int. 2013;4(S4):209-219.
Sehgal V, Delproposto Z, Haddar D, et al. Susceptibility weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J Magn Reson Imaging. 2006;24(1):41-51.
Haller S, Vernooij MW, Kuijer JPA, Larsson EM, Jager HR, Barkhof F. Cerebral Microbleeds: Imaging and Clinical Significance. Radiology. 2018;287(1):11-28.
Blitstein MK, Tung GA. MRI of cerebral microhemorrhages. AJR Am J Roentgenol 2007;189(3):720-725.
Lee S, Bae H, Yun U. Atypical Hemorrhagic Brain Metastases Mimicking Cerebral Microbleeds. Neurocrit Care. 2017;10(2):129-131.
Halefoglu AM, Yousem DM. Susceptibility weighted imaging: Clinical applications and future directions. World J Radiol. 2018; 10(4):30-45.
Gasparotti R, Pinelli L, Liserre R. New MR sequences in daily practice: susceptibility weighted imaging. A pictorial essay. Insights
Imaging. 2011;2(3):335-347.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Asian Medical Journal and Alternative Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
